Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. WBD
3. NVDA
4. PSKY
5. TSLA
6. AMD
7. USO
8. META
9. AMC
10. MSFT

Go back to Exelixis Announces U.S. FDA Grants Priority Review for CABOMETYX® (Cabozantinib) as a Treatment for Previously Untreated Advanced Renal Cell Carcinoma
Exelixis, Inc. (NASDAQ: EXEL) Delayed: 57.17 -1.19 (2.04%)
Previous Close $58.36    52 Week High $17.00 
Open $58.61    52 Week Low $3.55 
Day High $58.81    P/E N/A 
Day Low $56.90    EPS $-1.33 
Volume 878,917